We are IntechOpen, the world’s leading publisher of Open Access books
Built by scientists, for scientists

3,800
Open access books available

116,000
International authors and editors

120M
Downloads

154
Countries delivered to

TOP 1%
Our authors are among the most cited scientists

12.2%
Contributors from top 500 universities

WEB OF SCIENCE™
Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com
Neuroendocrine Tumours of the Lung

Guadalupe Aparicio Gallego¹, Vanessa Medina Villaamil¹, Ana Capdevila Puerta², Enrique Grande Pulido³ and L.M. Antón Aparicio⁴,⁵

¹Biomedical Research Institute, A Coruña University Hospital, A Coruña, ²Anatomic Pathology Service, A Coruña University Hospital, A Coruña, ³Medical Oncology Service, Ramon y Cajal University Hospital, Madrid, ⁴Medical Oncology Service, A Coruña University Hospital, A Coruña, ⁵Medicine Department, University of A Coruña, A Coruña, Spain

1. Introduction

Lung cancer arises from neoplastic changes of the epithelial cells in the lung. However, it is not known whether all or only a subset of these lung epithelial cells is susceptible to malignant transformation. Specifically, a major question is whether the changes need to take place in lung epithelial cells involving stem-cell-like properties. Lung cancer is a clinically, biologically, histologically, molecularly, and genetically heterogeneous disease. The underlying causes of this heterogeneity are unknown and could reflect changes occurring in cells with various potential for differentiation or represent different molecular changes occurring in the same lung epithelial target cells. Transformation from a normal to malignant lung cancer phenotype is thought to arise in a multistep fashion, through a series of genetic versus epigenetic alterations, ultimately evolving into an invasive cancer by clonal expansion. These progressive pathological changes in the bronchial epithelium occur primarily as one of three distinct morphological forms: squamous dysplasia, atypical adenomatous hyperplasia, and diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. Bronchial squamous dysplasia and carcinoma in situ (CIS) are the recognised preneoplastic lesions for squamous cell carcinoma (SCC); atypical adenomatous hyperplasia (AAH), a putative preneoplastic lesion, for a subset of adenocarcinomas (ADC); and diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) for neuroendocrine lung carcinomas. Pulmonary neuroendocrine tumours comprise approximately 2% of all lung malignancies. According to the most recent World Health Organization classification, pulmonary neuroendocrine tumours are histologically divided into a three-tier, four-category system including low-grade (typical carcinoid), intermediate-grade (atypical carcinoid), and high-grade (small cell carcinoma and large cell neuroendocrine carcinoma) tumours. Nearly all lung cancers exhibit the morphological and molecular features of epithelial cells and are accordingly classified as carcinomas. The cells of origin of virtually all lung cancers reside in the epithelial lining of the airways. As more is learned about the origin of neuroendocrine lung tumours, it is also increasingly clear that the biology of neuroendocrine lung tumours arising in the central airways (i.e., SCLC) is distinct from that of peripheral airway lesions. The purpose of this chapter is not so much to recapitulate the
details of the neuroendocrine lung tumour classification but rather to provide an understanding of the main categories of lung carcinoma, to highlight potential pitfalls in the histopathological diagnosis of lung cancer, to summarise current information on molecular properties and cellular origins of individual neuroendocrine lung tumour subtypes, and to relate pathologies to biological behaviours.

2. Neuroendocrine system of the lung

The endocrine cells within the gut epithelium (foregut, midgut, and hindgut) constitute the largest population of hormone producing cells in the body. So far, approximately 10 different neuroendocrine lineages have been identified, and most of them show a specific rostro-caudal distribution. Pulmonary neuroendocrine cells (PNECs) are part of the diffuse neuroendocrine system (DNES) distributed throughout the body. The PNEC system (solitary PNECs and neuroepithelial bodies, or NEBs) consists of a distinct population of airway epithelial cells displaying endocrine and paracrine secretory mechanisms. Pulmonary neuroendocrine cells were readily demonstrated and uniformly distributed in normal adult human lungs. Overall, as identified by neurone specific enolase immunoreactivity, there were 10.5 neuroendocrine cells per 10 cm of epithelial length and 4 per 10,000 epithelial cells; they extended from the trachea to the alveolar ducts but none was seen in the alveoli (72% were in bronchi, 24% in bronchioles, and 4% in alveolar ducts). Of the cells identified by gastrin-releasing peptide immunoreactivity, there were 6.9 neuroendocrine cells per 10 cm of epithelial length and 2.4 per 10,000 epithelial cells. Of the cells identified by calcitonin immunoreactivity, there were 3.5 neuroendocrine cells per 10 cm of epithelial length and 1.3 per 10,000 epithelial cells. Minor cells contained serotonin (all in the terminal bronchioles), and in a small minority no peptide or amine was detected. It is currently thought that PNECs, like their counterparts in the gastrointestinal tract, are derived from multipotent epithelial progenitors, and that all epithelial cells arise from a single stem cell. All pulmonary epithelial cells including PNECs and non-NE airway epithelial cells are likely to be derived from a single stem cell. Epithelial lung stem cells, as in many organs, are often confined to discretely localised niches that are protected from environmental insults. In the lung, PNECs are associated with the stem cell niches in both the proximal and distal airways. One of the lung stem-cell niches is located in the trachea that reveals two stem-cell niches: gland ducts in the proximal compartment and select foci near the cartilage-intercartilage junction in the distal trachea. Other intrapulmonary stem cell niches include NEBs located at the airway bifurcation. Another stem cell niche is at the bronchoalveolar junctions, although PNECs may play a diminished role at this location. Among many functions assigned to them, there is a possible dual role: the regulation of lung maturation/growth and chemoreception. First, during the early stages of lung organogenesis, PNECs acting via their amine and peptide products may function as local modulators of lung growth and differentiation. Second, in foetal life and in postnatal stages, PNECs and in particular innervated NEBs could play a role as airway chemoreceptors. The diffuse neuroendocrine system (DNES) of the lung involves neuroendocrine cells that have been shown to express a functional oxygen sensing mechanism. Aggregates of neuroendocrine cells, called neuroepithelial bodies (NEBs), are diffusely spread in the epithelium at all levels of the intrapulmonary airways, preferentially located at the airway bifurcation of the lungs. Neuroendocrine cells are selectively contacted by different nerve fibres. NEBs are contacted by at least three different nerve-fibre
populations: vagal sensory calbindin D28k, calcitonin gene related peptide (CGRP)/substance P (SP) innervation, and intrinsic pulmonary nitrergic neurons.

2.1 Neuroendocrine epithelial cells

Neuroendocrine epithelial cells (NEC) of the respiratory system tend to occur either as single cells that are sparsely distributed throughout the epithelium of the tracheobronchial tract or in small, well-defined clusters that are supported by nonciliated bronchiolar (Clara) cells. The latter are referred to as neuroepithelial bodies (NEBs) and are located only in the epithelium of the intrapulmonary airways, often at or near a bronchiolar bifurcation. The solitary pulmonary NEC cells of most of the investigated species are fusiform or flask-shaped, resting on the basement membrane with an apical process pointing toward the airway lumen. Adult human NEC cells generally lack luminal contact. Although there are some differences between solitary NEC cells and NEBs, a large body of evidence points to their being a member of the amine precursor uptake and decarboxylation (APUD) cell series or of the paraneuron family. The endocrine system of the lung consists of at least two different cell categories. These categories exhibit similar main characteristics. They contain a biogenic amine and neuropeptide mediators, and their cytoplasm harbours neurosecretory-like granules. Regarding morphological features and location, these cells presumably have a receptor secretory function. Consequently, these classes of endocrine cells can be designated as paraneurons. Solitary NEC cells were found to be distributed over almost the entire respiratory system, while NEBs seemed to be restricted to the epithelium of the intrapulmonary airways. Neuroepithelial bodies generally consist of nonciliated, cylindrical cells with a palisade-like arrangement between the airway surface and the underlying connective tissue, although they may also appear as stratified cells. Most of the luminal side of the NEBs is covered by the supporting Clara cells. The NEBs are strategically located on the surface of the airway bifurcations. They, in fact, contain the serotonin-bioactive amine and neuropeptides, leading to the speculation of these cells as a homogeneous or heterogeneous class. They also exert control on pulmonary vessels and airway tone. The NEC cell may function as the transducer of the stimulus or the sensory nerve ending, the activity of the latter being modulated by the release of bioactive substances from NEC cells. Investigations have indicated the influence of NEC cells on epithelial cell differentiation, mucous secretion, and proliferation of local endoderm in developing airways.

2.2 Pulmonary neuroendocrine cells

Pulmonary neuroendocrine cells (PNECs) are commonly organised into innervated clusters, called NEBs, which have been proposed to serve various functions, including the regulation of embryonic lung growth and maturation through the elaboration of a variety of potent neuropeptides. Several studies have suggested that PNECs are quiescent cells with limited self-renewal capacity. However, it was recently demonstrated that PNECs have a self-renewal capacity and can be activated to undergo multiple rounds of proliferation after TA (Clara) cell depletion. It has been suggested that PNEC-derived paracrine factors might play a role in the regulation of epithelial cell differentiation and proliferation during foetal lung development and possibly in the normal or injured adult lung. Cell proliferation has also been shown to contribute to the maintenance of PNE cells in the normal lung as well as in hyperplasia of this population in various disease states. PNE cells are known to act as a progenitor cell for the establishment of NEB hyperplasia and represent one of two
proliferative populations within hyperplastic NEBs of the naphthalene-injured lung. Participation of non-PNE progenitor cells in this process has also been demonstrated and may contribute to the intermediate phase of NEB hyperplasia. These data suggest that multiple cell types contribute to the maintenance and expansion of the NEB-associated PNE population and that progenitor selection may be a dynamic feature of NEB hyperplasia. Findings from various studies have established PNE cells as a progenitor population that is sufficient for the development of both NEB hypertrophy and hyperplasia. Although NEB dysplasia is correlated with preneoplastic conditions and PNE cells are thought to serve as a precursor for the development of small cell lung carcinoma, mechanisms regulating the expansion of the PNE cell population are not well understood. Based on studies performed in animal models, it has been suggested that NEB-associated progenitor cells that are phenotypically distinct from PNE cells contribute to PNE cell hyperplasia. However, when considering mechanisms that may account for PNE cell hyperplasia, the finding that multiple cell types proliferate in the NEB microenvironment raises the possibility that a non-PNE cell progenitor may yield progeny cells with the capacity to undergo PNE cell differentiation.

2.3 Neuroepithelial bodies

Neuroendocrine bodies were illustrated in 1949 in the description of neuroendocrine cells in the bronchiolar mucosa. Neuroendocrine bodies consist of a cluster of 4 to 10 neuroendocrine cells. On well-oriented sections, they can extend from the subepithelial basement membrane to the airway lumens. They are found not only in the epithelium of bronchi and bronchioles, but also in alveoli. The neuroepithelial body (NEB) is a highly dynamic structure that responds to chronic airway injury through hyperplasia of the associated PNEC. NEB-associated epithelial cells share many morphological and biochemical characteristics with cells that are distributed throughout the airway. Pulmonary NEBs are prime candidates to serve as sensory end organs in the lung. NEBs consist of highly organised clusters of specialised cells with neuroendocrine characteristics, arranged into organoids that are dispersed throughout the epithelium at all levels of the intrapulmonary airways. Structurally, NEB cells harbour cytoplasmic neurosecretory granules that are known to contain monoamine, peptide, and purine transmitters. Neuroendocrine cells are able to synthesise and release ATP, monoamine, and peptide transmitters, resulting in autocrine, paracrine, or endocrine effects. Morphologically, NEBs resemble other known chemoreceptors, such as taste buds and carotid bodies, and are thought to represent “chemosensors” among other possible functions. Hypoxic conditions appear to depolarise NEB cells via a potassium channel-mediated mechanism. In particular, the extensively innervated aggregates of the neuroendocrine cells, called neuroepithelial bodies (NEBs), are diffusely spread in the epithelium at all levels of the intrapulmonary airways but are preferentially located at the airway bifurcation points in the lungs. Proportionally, most NEBs are found in the bronchioles and in the terminal respiratory bronchioles. The NEB microenvironment may represent an analogous structure within the conducting airway epithelium for maintenance of an airway stem-cell pool. It may influence the phenotype of the CE cells, blocking the differentiation from Clara to ciliated cells and preserving a population of regenerative cells that can contribute to epithelial renewal after exposure to Clara cell toxicants. Regeneration of the chronically injured airway epithelium is associated with alterations in the number and cellularity of the NEBs.
as well as the enrichment of nascent epithelial cell populations of epithelial cells that are
candidate stem cells. The NEB microenvironment is multifunctional, serving to maintain
slow-cycling epithelial cells in the steady state epithelium and to stimulate the
proliferation of TA cells either after airway injury or during airway development. Many
studies have presented extensive evidence that NEBs in the lungs may be selectively
contacted by at least 5 distinct nerve-fibre populations that are both sensory and motor in
nature. In addition, they have different origins, indicating that NEBs should be regarded
as very complex airway receptors that may be capable of accommodating various chemo-
and mechano-sensory modalities.

2.3.1 Functions
It has been estimated that NEBs represent <1% of the epithelial cells in human lungs.
Some of the supposed functions of NEB in mammalian lungs include the following: 1) the
ability of NEB to function as transducers (hypoxia); 2) modulation of bronchomotor tone via
targeting bronchial smooth muscle and the associated nerves located directly beneath NEB;
3) promotion and regulation of the growth of developing airways by stimulating the
proliferation of local endoderm; 4) release of amine and peptide modulators; and 5) neonatal
respiratory adaptation. The lung bud epithelium grows into the adjacent mesenchyme and
stars branching to form the future bronchial tree. The various stages are divided into the
embryonic, pseudoglandular, canalicular, saccular and alveolar/microvascular periods.
Pulmonary neuroendocrine cells are the first specialised epithelial cell type to appear in
lung development. In humans, ultrastructurally distinct primitive PNECs (pre-NE cells),
which contain serotonin and neuro-specific enolase (NSE), can be detected in the beginning
of the pseudoglandular period. Solitary and clustered PNECs contain bombesin, the major
neuropeptide in human lungs, which appears in the early weeks of gestation. As the distal
segments of the developing airways elongate, a process referred to as the canalicular period,
PNECs differentiate first, followed by ciliated and secretory (Clara) cells. Parallel with the
increasing number of peripheral airways, the number of PNECs also increases. In the
developing bronchioles, small NEBs composed of 3-5 bombesin and serotonin-
immunoreactive cells appear at the airway branching points, and rare nerve endings have
been demonstrated to be in contact with NEBs already in the human foetal lung. Proposed
roles for PNECs in foetal and newborn lung development include the regulation of
branching morphogenesis as well as cellular growth and maturation.

2.3.2 Airway oxygen sensors
Since 1930, evidence has accumulated to suggest that NEBs may function as hypoxia-
sensitive airway sensors. NEB cells express membrane-bound O\textsubscript{2} sensors and are the
transducers of the hypoxic stimulus. NEB cells respond to acute hypoxia, but apparently not
to hypercapnia with the degranulation of dense core vesicles and release of 5-
hydroxytryptamine (5-HT). Morphologic and experimental studies to support NEB
functions as hypoxia-sensitive airway chemoreceptors modulated by the central nervous
system include the following: a) preferential location of NEB at airway branching points; b)
apical microvilli in contact with the airway lumen; c) cytoplasmic neurosecretory granules
containing monoamine and neuropeptides; d) afferent sensory innervation derived from the
vagus nerve; and e) proximity to blood capillaries. NEBs are predominantly innervated by
sensory nerve fibres derived from cell bodies in the nodose ganglion of the vagus nerve.
Morphological data support the role of NEBs as hypoxia-sensitive airway sensor systems. Studies on the effects of chronic hypoxia have shown induced cellular hyperplasia and hypertrophy in the peripheral chemoreceptors; chronic normobaric hypoxia showed a significant increase in the number of solitary pulmonary neuroendocrine cells (PNECs) as well as the enlargement of NEBs. NEB cells possess an oxygen-binding protein, cytochrome $b$, an NADPH oxidase located in the cellular membranes that acts as the $O_2$ receptor both during normoxia and hypoxia.

3. Pathology of neuroendocrine tumours of the lung

The neuroendocrine cell system is divided into cell types that form glands and diffusely distributed cells. This second group is collectively known as the diffuse neuroendocrine system (DNES), and its representatives are found in the lung, gastrointestinal tract, or urogenital tract. Neuroendocrine tumours of the lung arise from bronchial mucosal cells known as Kulchitsky cells, which are part of the DNES. The classification of lung neuroendocrine malignancies has been an evolving process (Table 1).

<table>
<thead>
<tr>
<th>WHO/IASLC histological classification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preinvasive Lesions</td>
</tr>
<tr>
<td>Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH)</td>
</tr>
<tr>
<td>Large Cells carcinoma (Variants)</td>
</tr>
<tr>
<td>Large cell neuroendocrine carcinoma (LCNEC)</td>
</tr>
<tr>
<td>Combined large cell neuroendocrine carcinoma (C-LCNEC)</td>
</tr>
<tr>
<td>Carcinoid tumour</td>
</tr>
<tr>
<td>Typical carcinoid (TC)</td>
</tr>
<tr>
<td>Atypical carcinoid (AC)</td>
</tr>
<tr>
<td>Small cell carcinoma</td>
</tr>
<tr>
<td>Combined small cell carcinoma</td>
</tr>
<tr>
<td>Non-small Cell Lung Carcinoma with Neuroendocrine Differentiation (NSCLC-NED)</td>
</tr>
</tbody>
</table>

Table 1. Lung tumours with neuroendocrine morphology include the low-grade typical carcinoid (TC), intermediate-grade atypical carcinoid (AC), and the high-grade LCNEC and SCLC.

These classifications date back to 1972, when atypical carcinoids were initially defined according to histological criteria, including the number of mitoses per high-power field (hpf), the presence of necrosis, increased cellularity with disorganisation, nuclear pleomorphism, hyperchromatism, and an abnormal nuclear to cytoplasmic ratio (Table 2). In 1991, a new classification proposed 4 categories of neuroendocrine lung tumours that included the following: typical carcinoid (TC), which is a low-grade malignancy; atypical carcinoid (AC), which is a medium-grade malignancy; large-cell neuroendocrine carcinoma (LCNEC), which is a high-grade malignancy; and small-cell lung cancer (SCLC), which is also a high-grade malignancy. The 2004 WHO categorisation of tumours with neuroendocrine features included the classic carcinoid low-grade TC and intermediate-grade AC, as well as the high-grade malignancies LCNEC and SCLC.
Neuroendocrine Tumours of the Lung

Table 2. Histopathological Classification of Neuroendocrine Tumours of Lung

<table>
<thead>
<tr>
<th>Tumor</th>
<th>Mitoses</th>
<th>Nuclear chromatin</th>
<th>N/C ratio</th>
<th>Nucleoli</th>
<th>Necrosis</th>
<th>Shape</th>
</tr>
</thead>
<tbody>
<tr>
<td>TC</td>
<td>&lt;2/10 HPF</td>
<td>Finely granular, occasional atypia</td>
<td>Moderate</td>
<td>Occasional</td>
<td>None</td>
<td>Round, oval</td>
</tr>
<tr>
<td>AC</td>
<td>2-10/10 HPF</td>
<td>Finely granular</td>
<td>Moderate</td>
<td>Common</td>
<td>+(focal)</td>
<td>Round, oval</td>
</tr>
<tr>
<td>SCLC</td>
<td>≥11/10 HPF</td>
<td>High</td>
<td>Absent or inconspicuous</td>
<td>+ (large zones)</td>
<td>Round, oval, spindle</td>
<td></td>
</tr>
<tr>
<td>LCNEC</td>
<td>&gt;11/10 HPF</td>
<td>Vesicular or coarsely granular</td>
<td>Low</td>
<td>Very common</td>
<td>+(large zones)</td>
<td>Round, oval, polygonal</td>
</tr>
</tbody>
</table>

N/C: nuclear/cytoplasmic; HPF: high power fields; LCNEC: large cell neuroendocrine carcinoma; SCLC: small cell lung carcinoma

3.1 Tumourlets
Carcinoid tumours that grow in the peripheral lung and are smaller than 5 mm are referred to as tumourlets. By definition, tumourlets are comprised of increased numbers of individual cells, small group cells, or nodular aggregates of cells that are confined to the bronchial/bronchiolar epithelium (with larger lesions bulging into the lumen but not breaking the subepithelial basement membrane).

3.2 Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is a rare condition in which neuroendocrine cells proliferate throughout the peripheral airways in the form of neuroendocrine cell hyperplasia, tumourlets, and sometimes carcinoid tumours. In DIPNECH, neuroendocrine cell hyperplasia and tumourlets are thought to be a primary proliferation in contrast to the much more common situation where these lesions are seen as a reactive secondary lesion in the setting of airway inflammation and/or fibrosis. This condition is regarded as a precursor to carcinoid tumours because a subset of these patients experience one or more carcinoid tumours. More aggressive forms of lung carcinoma, including SCLC, have not been associated with DIPNECH.

3.3 Carcinoid tumours
Pulmonary or bronchial carcinoid tumours account for over 25% of all carcinoid tumours and for 1%-2% of all pulmonary neoplasms. Approximately 10%-20% of pulmonary carcinoids are typical carcinoids; the remaining 80%-90% are atypical carcinoids. Most of these tumours occur centrally and involve the main, lobar, or segmental airways. Sometimes they are located distal to the segmental bronchi; such tumours are the so-called peripheral carcinoids. Atypical carcinoids have been reported to be larger than typical carcinoids, with mean diameters of 3.6 cm and 2.3 cm, respectively. Moreover, atypical carcinoids are more likely to occur in the periphery of the lung than are typical carcinoids. It was generally accepted that a carcinoid tumour was a very slow-growing and benign neoplasm with no potential for invasiveness and no tendency to give rise to metastases. Carcinoid tumours have subsequently been reported in a wide range of organs, but they most commonly
involve the lungs and the gastrointestinal tract. The histopathologic features that distinguish atypical carcinoids from typical carcinoids are as follows: increased mitotic activity; greater cytological pleomorphism and higher nuclear to cytoplasmic ratios; increased cellularity and architectural irregularities, and more areas of tumour necrosis. In terms of histological features, typical carcinoids show no evidence of necrosis and fewer than 2 mitoses per 10 high-power fields (or 2 mm²) of viable tumour, whereas atypical carcinoids do have areas of necrosis and 2-10 mitoses per 10 high-power fields.

3.4 Large-Cell Neuroendocrine Carcinoma

Large-cell neuroendocrine carcinoma (LCNEC) was proposed as the fourth category of pulmonary neuroendocrine tumours due to its distinct clinical and pathologic findings versus the typical carcinoid, atypical carcinoid, and SCLC. LCNEC is defined as a poorly differentiated and high-grade neuroendocrine tumour that morphologically is between an atypical carcinoid and SCLC. According to the WHO suggestions, the morphologic features of LCNEC represent a spectrum between those of atypical carcinoid and those of SCLC. In 70%-80% of cases, LCNEC appears as a peripheral mass or nodule, whereas 25% manifests as a central mass. Histopathologic diagnosis criteria for LCNEC are as follows: neuroendocrine morphologic features; a high mitotic rate (>10 per 10 high-power fields); necrosis (often large zones); cytologic features different from those of SCLC; and positive immunohistochemical staining for one or more neuroendocrine markers including chromogranin A, synaptophysin, and neural cell adhesion molecular (NCAM/CD56).

3.5 Small-cell lung carcinoma

SCLC accounts for approximately 20% of all bronchogenic carcinomas. Approximately 90%-95% of SCLCs occur centrally, apparently arising in a lobar or main bronchus. In 5%-10% of cases, SCLC manifests as a peripheral nodule. These tumour cells are usually small with a round or fusiform shape and have high cellularity with a very high mitotic rate. SCLCs are highly proliferative and rarely are the mitotic rates less than 10 mitoses per 10 high-power fields. As such, virtually every high-power field contains one or more mitoses. The architecture of the tumour clusters is poorly preserved, with large areas of necrosis separating small islands of viable tumour. A distinguishing feature of SCLC is its expression of neuroendocrine markers including neuron specific enolase (NSE), synaptophysin, neural cell adhesion molecule (NCAM/CD56), and Leu-7 (CD57).

4. The neuroendocrine differentiation in lung tumours

4.1 Non-small cell lung cancer (NSCLC)

The hypothesis that tumours with neuroendocrine properties should be grouped into a single category is not universally accepted for several reasons. First, a large proportion of lung carcinomas have mixed non-neuroendocrine and neuroendocrine properties. This is particularly evident in molecular profiling studies where otherwise unremarkable adenocarcinomas have been shown to express clusters of genes that are thought to reflect neuroendocrine differentiation. Second, many of the markers that are regarded as neuroendocrine markers are expressed in a variety of cells in addition to neuroendocrine cells. Third, neuroendocrine markers are expressed during the embryonic development of the lung.
4.1.1 Adenocarcinoma (ACA)
Pathology reports frequently mention the presence of NE immunophenotype or NE differentiation in NSCLC. Travis et al. have provided a new classification of the pulmonary NE proliferations and neoplasms of the lung, as part of the WHO classification of lung cancers. In this classification, NSCLC with NE differentiation (NSCLC-ND) detected only by immunostaining via electron microscopy is presented as a distinct entity in which no histological features of NE differentiation are appreciated on routine hematoxylin and eosin (HE). NSCLC represents a histologically heterogeneous group of tumours with variable clinical behaviours. Evidence for NE differentiation in non-small cell lung carcinomas (NSCLCs) is, at present, based on histochemical, ultrastructural, and immunohistochemical data. The existence of nonsmall cell lung carcinoma with neuroendocrine differentiation as a distinct entity, as well as its relevance for prognostic and treatment purpose, is controversial. A minority of NSCLCs (10-30%) show NE differentiation, and in contrast to large cell NE carcinoma, they show no evidence of this differentiation on routine light microscopic examination. Previous studies have identified NE differentiation in NSCLC in 10 to 70% of cases. Positivity for all 3 NE (Ch, SNP, and CD56) markers was not seen. The co-expression of SNP and Ch, the two most commonly used NE markers, accounted for only 0.2% (ACA) of the NSCLC. SNP staining was observed in a significant minority of NSCLC (7.5%), whereas Ch, the most specific NE marker, was very uncommon (0.4%) (Table 3).

<table>
<thead>
<tr>
<th>NSCLC Cell Type</th>
<th>Chromogranin (Ch)</th>
<th>Synaptophysin (SNP)</th>
<th>N-CAM (CD56)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adenocarcinoma</td>
<td>0.4%</td>
<td>11.2%</td>
<td>5.1%</td>
</tr>
<tr>
<td>Squamous cell carcinoma</td>
<td>0.4%</td>
<td>4.3%</td>
<td>12.4%</td>
</tr>
<tr>
<td>Non-small cell carcinoma</td>
<td>0%</td>
<td>12%</td>
<td>7.4%</td>
</tr>
<tr>
<td>Large cell carcinoma</td>
<td>0%</td>
<td>9.3%</td>
<td>6.2%</td>
</tr>
<tr>
<td>Others</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
</tr>
</tbody>
</table>

Table 3. Immunoreactivity for Neuroendocrine Markers in Different Subtypes of NSCLC

As has been suggested, the derivation of all lung tumours from a common endodermal stem cell, along with the adoption of amine precursor uptake and decarboxylation properties by this endodermal stem cell, explains divergent differentiation in NE lung tumours and the occurrence of NE subsets in NSCLC.

4.1.2 Large cell carcinoma (LCC)
Large cell carcinomas of the lung are classified into four types based on light microscopic evidence of neuroendocrine morphology. Immunohistochemical or electron microscopic assessments of neuroendocrine differentiation are categorised as follows: (1) large cell neuroendocrine carcinoma exhibits both neuroendocrine morphology and evidence of neuroendocrine differentiation; (2) large cell carcinoma with neuroendocrine differentiation exhibits neuroendocrine markers but lacks neuroendocrine morphology; (3) large cell carcinoma with neuroendocrine morphology exhibits neuroendocrine markers; and (4) classic large cell carcinoma exhibits neither neuroendocrine morphology nor differentiation. Neuroendocrine markers in NSCLC are expressed not only in large cell carcinoma but also in adenocarcinomas.
4.2 NETs of the lung with NE differentiation

Lung tumours with neuroendocrine morphology include the low-grade typical carcinoid (TC), intermediate-grade atypical carcinoid (AC), and the high-grade LCNEC and SCLC. Neuroendocrine differentiation may be detected by immunohistochemical or ultrastructural studies in 10% to 20% of histologically ordinary NSCLCs such as squamous cell carcinomas, adenocarcinomas, or large cell carcinomas.

4.2.1 Small cell lung carcinoma (SCLC)

SCLC tumors are considered poorly differentiated NE cancers in contrast to typical and atypical bronchial carcinoid tumors. In addition to SCLC, approximately 20-30% of NSCLC tumors express some degree of NE differentiation, predominantly in adenocarcinomas and large cell cancers. SCLC exhibits characteristic molecular abnormalities which partially overlap with those of NSCLC including frequent inactivation of the Rb-p16INK4A-related G1 checkpoint pathway, loss of p53, and frequent abnormalities in chromosome

Fig. 1. Hypothetical carcinogenetic pathway in lung cancer: The specification of distinct cell fates is often achieved through the activation of specific intercellular signaling pathways by growth factors whose expression must be spatially and temporally controlled to ensure accurate response. Typically, a target cell expresses an excess of receptors such that the availability of its ligands is rate-limiting for pathway activation. Overall, for a signal to elicit the desired response, the intensity and duration of ligand expression must be sufficient to meet its threshold concentration, and yet the signal response must be restricted to prevent excessive signaling. Excessive activation of a signaling pathway can have broad deleterious effects, thus prompting a requirement for antagonistic regulation. Abbreviations: AAA (Atypical Adenomatous Hyperplasia), ADC (Adenocarcinoma), BAC (Bronchioalveolar Carcinoma), BSD (Basal Squamous Dysplasia), DIPNECH (Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia), LCC (Large Cell Carcinoma), LCNEC (Large Cell Neuroendocrine Carcinoma), NEBs (Neuroepithelial Bodies), PNCs (Pulmonary Neuroendocrine Cells), SCC (Squamous Cell Carcinoma), SCLC (Small Cell Lung Carcinoma).
3p-associated tumor suppressor activity. In addition to these changes, SCLCs frequently overexpress myc genes, especially c-Myc, often via gene amplification events. Of all the genetic changes in SCLC, Rb gene mutations are utterly characteristic. Functioning RB protein is lacking in greater than 90% of SCLC and NSCLC with NE features.

4.2.2 Large cell neuroendocrine carcinoma (LCNEC)
The term combined LCNEC is used for those tumours associated with other histologic types of NSCLC. Most often this represents a component of adenocarcinoma. LCNEC must be distinguished from adenocarcinoma, SCLC, large cell carcinoma, and large cell carcinoma with neuroendocrine differentiation (LCC-ND).

5. Embryological pathways in lung tumours
5.1 Notch
The three main functions of Notch signalling in self-renewing tissues include stem-cell maintenance, binary cell-fate decisions, and induction of differentiation. A critical aspect of Notch function in both development and post-natal life is the maintenance of stem cell viability and asymmetric cell division. Intrinsic to this process is an unequal distribution of Notch signals in the daughter cells, with the Notch-active cell maintaining its stem cell

www.intechopen.com
character and with transit-amplifying cells typically losing Notch activity. Interestingly, Notch function in lung cancer exhibits properties suggesting both tumour promotion and inhibition, depending on the tumour cell type. A prominent function of Notch signalling is to inhibit the transcriptional activities of the widely expressed E2A proteins. Notch signalling rapidly induces degradation and inactivation of E proteins and tissue-specific bHLH proteins such as hASH1. This inhibition may occur as a consequence of forming inhibitory complexes of E2A proteins with the Hes/HERP/HEY proteins, as well as the promotion of E2A protein ubiquitinylation and degradation by Notch. Notch1 and Notch2 proteins are frequently expressed in non-small-cell lung cancer (NSCLC), while Notch3 mRNA expression was detected in one-third of all NSCLC cell lines. NSCLC, which includes adenocarcinoma, squamous cell carcinoma, large cell undifferentiated carcinoma, and bronchoalveolar cell carcinoma, was initially shown to express significant levels of the Hes1 protein. In addition, there is an inverse correlation in these cell lines between the expressions of hASH1/ASCL1 and of the Hes1 protein. In contrast to NSCLC, where Notch is suspected to have a growth promoting function, SCLC appears to be growth inhibited, at least by the high level over-expression of activated Notch1 and Notch2. Notch1 is rarely detectable or inactive in SCLC, whereas a subset of SCLC exhibit Notch2. Notch3 mRNA expression was not detected in the SCLC cell lines. Expression of Notch3 has been reported to be common in NSCLC but not in SCLC. Significantly, Notch signaling has recently been shown to be induced by the ras pathway, which is active in a large fraction of NSCLC, but
only rarely in SCLC. Notch in the SCLC cells lead to a significant increase in Hes1 and a
marked down-regulation of the neurally related transcription factors hASH1 and Hes6. The
loss of hASH1 may be critical in mediating the growth inhibitory effect of Notch1 in SCLC,
although a role for other as yet unidentified targets cannot be excluded. Activated Notch1
and Notch2, but not Hes1, caused a potent G1 arrest in the SCLC cells, accompanied by the
marked up-regulation of p21^{wasl/cip1}, overall abundance of p53, and a Rb mutant typifying
the majority of SCLC.

5.2 Hedgehog signalling in lung cancer
The hedgehog (Hh) signalling network functions in cell-cell communication and regulates
pattern formation, proliferation, cell fate, and the stem/progenitor cell maintenance and self-
renewal in many organs. A greatly simplified version of “canonical” hedgehog signalling in
mammals typically involves two types of cells, a signalling cell expressing a member of the
Hedgehog family of secreted ligands (Sonic Hedgehog (Shh), Indian Hedgehog (Ihh), or Desert
Hedgehog (Dhh)) and a responding cell expressing one or more Patched family hedgehog
receptors (Patched-1 (PTCH2)). In the Hh pathway, increased signalling results in activation of
the GLI oncogenes (GLI1, GLI2, and GLI3) that can regulate gene transcription. The Hh
signalling pathway was originally shown to have persistent activation in SCLC with high
expression of Shh, PTCK, and GLI1, but an important role in NSCLC, was also demonstrated.

5.3 BMPs and BMPRs
The BMPs comprise a branch of the TGF-β superfamily that also plays a key role in
development. Several BMP ligands and BMPRs including BMP3, 4 and 7 as well as type I
BMPR are expressed during embryonic lung development. BMP4 mRNA is localized at high
levels in the epithelium of distal tips of terminal buds, with lower levels in the adjacent
mesenchyme. These loci of BMP expression overlap with the expression domains of some
other important morphogenetic signaling molecules including HNF-3β, Wnt-2, Shh and
FGF-10. Also, since BMPs and Shh are co-expressed in the same domains, and since
Decapentaplegic, the Drosophila BMP homologue, is regulated by the Hedgehog signaling
pathway, it seems possible that BMP-Shh interactions may prove to play key roles in lung
morphogenesis. Recently published data on fibroblast growth factor interactions suggest
that Shh, TGF-β1 and BMP4 all counteract the bud-promoting effects of FGF-10.

5.4 Wnt pathway in lung cancer
Wnt signaling has many functions in animal development including its development role in
embryogenesis and in the adult lung. More specifically, studies of knockout mice
demonstrated the importance of Wnt-2, Wnt-5a, and Wnt-7b in lung maturation. In addition
to its role in stem cell self-renewal, tissue regeneration, and lung development, Wnt
signaling is also intimately involved in tumorigenesis and cancer progression. For example,
the organs where Wnt signaling influences stem cell self-renewal are the same organs where
those Wnt-pathway-dependent cancers originate. Numerous reports have demonstrated
aberrant Wnt activation in lung cancer. Overexpression of Wnt-1 has been demonstrated in
NSCLC cell lines and primary cancer tissues. This activation can be caused by mutations
and/or deregulation of many different Wnt signaling components. Mutations in Wnt
pathway components are rarely found in lung cancer. Also overexpression of Wnt-2 in
NSCLC has been demonstrated. The human Wnt-2 gene, located on chromosome 7q31.3, is
highly expressed in fetal lung. The link between Wnt-2 and tumorigenesis was first proposed after data indicated that Wnt-2 was amplified in human cancers. Indeed, in patients with NSCLC found that Wnt-5a expression is squamous cell carcinoma was significantly higher than that in adenocarcinoma. Recently there has been a suggested role for Wnt-7 in lung cancer. It has been reported that expression of Wnt-7a is downregulated in most lung cancer cell lines and tumor samples.

5.5 bHLH
Helix-loop-helix proteins are a diverse family of transcriptional regulators involved in fetal development and cancer. The 125 recognized human HLH proteins can be subdivided into 45 families, almost all of which have Drosophila representatives as well. These families include achaete-scute homologs, E proteins, Atonal, NeuroD, neurogenin, ID proteins, HES, and Hes-related proteins, and others. bHLH genes control cell differentiation in various tissues and are categorized into two distinct groups, activator genes and repressor genes. In mammals, bHLH genes such as mammalian achaete-scute complex homolog-1 (MASH1) and mammalian atonal homolog (MATH)-1 are expressed in neural precursor cells, and they up-regulate late-expressing bHLH genes such as NeuroD to direct terminal differentiation. On the other hand, HES1, one of the hairy and enhancer of split (HES) homologues, represses neuronal differentiation by the suppression of proneural bHLH factors. Repressive bHLH factors such as HES1 are regulated by the Notch pathway. The Notch ligands activate the Notch receptors, and the activated intracellular domain of the Notch receptors interacts with the DNA-binding protein RBP-Jk to activate the expression of repressive bHLHs such as HES1 and HES5, which, in turn, suppress the expression of activator bHLHs such as MASH1 and NeuroD. Immunohistochemical studies have revealed that Notch1, Notch3, Jagged1, and Jagged2 were expressed in neuroendocrine cells of the airway epithelium, while Dll1 was detected in the pulmonary neuroendocrine cells. Thus, the differentiation of the lung epithelial cells depends on a bHLH factor network, and the Notch pathway may be involved in determining the cell differentiation fate in the airway epithelium.

5.5.1 Achaete-scute homolog (ASH-1)
Mash1 (termed Hash1 in humans) plays a critical role in development of the central and autonomic nervous systems and in tissues of the so-called diffuse NE system including the adrenal medullary chromaffin cells, thyroid parafollicular C-cells, and pulmonary NE cells. MASH1 is important in the development of the diffuse neuroendocrine system, including pulmonary neuroendocrine cells. During neurogenesis, MASH1 expression is confined to mitotically active precursors where it is involved in the early stages of lineage commitment; in more mature neurons the expression is extinguished. MASH1 and mammalian atonal homolog-1 (Math1) up-regulate NeuroD in neural precursor cells to direct terminal differentiation, whereas HES1 represses neuronal differentiation by the suppression of proneural factors such as MASH1. In the developing mouse lung, Mash1 first becomes detectable at approximately E13.5 in neuroepithelial bodies (NEBs), clusters of NE cells frequently located at branchpoints of large and medium-sized airways. Mash1 expression in mouse lung peaks near birth and the declines in adulthood, following the peak and decline of lung NE cells. One target of achaete-scute proteins is the cell surface ligand delta, which leads to activation of the Notch pathway in adjoining cells and repression of the neuronal fate. In human lung tumours, the expression of hASH1 mRNA was significantly higher in
SCLC (75%) than in LCNEC (50%); conversely, HES1 mRNA was lower in SCLC (59%) than in LCNEC (87%). These findings reveal that SCLC more strongly expresses the neuroendocrine phenotype, while LCNEC shows characteristics that are more similar to the epithelium phenotype, suggesting that the biological characteristics of these two tumours are different. On the contrary, non-neuroendocrine carcinoma cells do not express hASH1 but show high HES1 expression. In NSCLC (squamous cell carcinoma vs. adenocarcinoma), the expression of hASH1 mRNA was lower, (0% vs. 15%, respectively), whereas HES1 mRNA was higher (10% vs. 100%, respectively). Neuroendocrine pulmonary carcinomas express MASH1 but not HES1, whereas adenocarcinoma and squamous cell carcinoma express HES1. Surprisingly, Merkel cell carcinoma, the cutaneous counterpart of small cell carcinoma MASH1, was completely negative in 100% of the cases.

5.5.2 Hairy and Enhancer-of-split (HES)
Hes1, a key effector of the Notch signalling pathway, is expressed broadly in non-neuroendocrine cells in the airway epithelium. In the developing lung, Notch1 and HES1 are strongly expressed in the non-neuroendocrine airway epithelial cells, whereas MASH1 is restricted to the clustered pulmonary neuroendocrine cells. HES1 directly represses hASH1 expression by binding to a class C site in the ASH1 promoter. Today, the published results suggest that the differentiation of neuroendocrine cells in normal lungs is affected by the absence of the MASH1 gene. Elements of the Notch signalling pathway, especially that of HES1, appear to be critical negative regulators of achaete-scute homolog 1 expression in normal lungs and in lung cancer. For example, HES1 transgenic knockout mice exhibit substantial hyperplasia and premature differentiation of lung NE cells associated with an increase in MASH1-expressing pulmonary epithelium. It has been shown that the over-expression of HES1 in SCLC cells leads to the repression of hASH1 expression via a transcriptional mechanism.

5.5.3 Retinoblastoma (Rb)
The RB gene is a prototypical tumour suppressor gene, and the loss of RB function is believed to be a key event in the initiation or progression of several human malignancies. Most RB gene alterations result in the loss of RB protein expression or in a truncated RB protein, which does not enter the nucleus. Thus, heterogeneous positive nuclear RB immunostaining is, in general, indicative of normal RB function, whereas negative intranuclear RB immunostaining in all tumour cells reflects aberrant RB protein expression. Typical and atypical carcinoids manifest a heterogeneous RB-positive staining pattern. Atypical carcinoids in general show an increase in the number of tumour cells with nuclear staining compared to typical carcinoids. In contrast, small-cell and large-cell neuroendocrine carcinomas fail to show RB staining in any tumour nuclei, indicating the loss of RB function. From these results, it can be concluded that a progressively higher degree of malignancy from typical carcinoids to atypical carcinoids to small-cell carcinomas is paralleled by the loss of neuroendocrine markers, increased proliferative markers, increased frequency of p53 immunostaining, and decreased frequency of RB immunostaining.

5.5.4 p53
Although p53 alterations have been previously studied in pulmonary neuroendocrine tumours, either these studies have used immunochemistry alone rather than genotypic
analysis or they have examined a limited spectrum of pulmonary neuroendocrine neoplasias. The distribution of p53 immunohistochemical staining has 4 patterns: negative in typical carcinoids (TCs), 50% of ACs, 20% LCNECs, and 12% SCLCs; less than 10% but more than 5-10 HPF (focal) in a subset (30%) of aggressive adenocarcinomas; and 50-100% of tumour cells (diffuse), exclusively seen in LCNECs and SCLCs. Three patterns of immunohistochemical staining intensities of the p53 protein were seen: negative; weak or mild; and moderate to marked staining. Similar to other cancers, multiple genetic events contribute to the development of neuroendocrine lung tumours. This has already been demonstrated in SCLCs, which are known to exhibit alterations in their oncogenes such as c-myc and in tumour suppressor genes such as p53 and Rb. In addition, it has been shown that alterations in oncogenes such as H-ras, c-myc, and c-raf-1 can modulate the expression of neuroendocrine antigens in lung cancer cell lines. Thus, evidence is accumulating that the expression of neuroendocrine differentiation in pulmonary neuroendocrine tumours is fundamentally controlled by multiple genetic determinants.

6. Conclusions

Although incidence of newly diagnosed patients with carcinoid tumors of the lung is low, the long survival for those with low and intermediate differentiation grade, and the deeper knowledge we now have on molecular processes that governs tumors growth make these tumors a challenging field in Oncology. Systemic treatment for metastatic carcinoid tumors of the lung has not change significantly in the last two decades, and this fact leads to a poor improvement in overall survival, contrary to what has happened in other solid tumors. Nowadays, most of researchers in neuroendocrine field consider that every single neuroendocrine tumors has its own features depending on the organ where it seats, the capacity to produce and secrete active hormones to blood stream, and the proliferation rate. Novel agents like antiangiogenic tyrosine kinase inhibitors, mTOR inhibitors or oral chemotherapeutic agents like temozolomide and capecitabine have been used to treat metastatic neuroendocrine tumors of the lung without a clear activity. Unfortunately, these clinical trials with new agents were not driven to lung tumors but to other neuroendocrine tumors of the gastrointestinal tract. Therefore, other pathways are needed to be investigated. A non insignificant number of recent publications are correlating embryological pathways with carcinoid tumors of the lung development. In this sense, some elements of the Notch signalling pathway, especially HES1, appear to be critical negative regulators of hASH-1 expression in normal lungs and in lung cancer. This fact may influence in carcinoid tumor development at this place. New compounds under clinical development targeting embryological pathways like Notch, Hedgehog or Wnt pathways may have a future impact in the treatment of disseminated carcinoids of the lung. The more we are able to select patients molecularly the greater the chance of success in future clinical trials conducted in this setting. However, none of this would be meaningless if the histological diagnosis is not accurate. There is a need to leverage the knowledge in the scientific community of the variety of neuroendocrine-derived tumors that may arise in the lung. The teamwork between pulmonologists, thoracic surgeons, pathologists, molecular biologists, oncologists, and radiotherapists is mandatory to offer to our patients the best treatment approach at the right time for their diseases.
7. References

7.1 Neuroendocrine system of the lung


Feyrter F. Über die peripheren endokrinen (parakrinen) Drüsen des Menschen. 1993; Maudrich. Vienna.


Pearse AG. The cytochemistry and ultrastrusture of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept. J Histochem Cytochem 1969;17:303-313


7.2 Neuroendocrine epithelial cells


7.3 Neuroendocrine epithelial cells & pulmonary neuroendocrine cells


7.4 Neuroepithelial body structure


Hong KV, Reynolds SD, Giangreco A, et al. Clara cell secretory protein-expressing cells of the neuroepithelial body microenvironment include a label-retaining subset and are critical for epithelial renewal after progenitor depletion. Am J Respir Cell Mol Biol 2001;24:671-681


www.intechopen.com


Reynolds SD, Giangreco A, Power JH et al. Neuroepithelial bodies of pulmonary airways serve as a reservoir of progenitor cells capable of epithelial regeneration. Am J Pathol 2000; 156: 269-278


7.5 Stem cells and neuroepithelial bodies


Reynolds SD, Giangreco A, Power JH et al. Neuroepithelial bodies of pulmonary airways serve as a reservoir of progenitor cells capable of epithelial regeneration. Am J Pathol 2000; 156: 269-278


### 7.6 Pathology of neuroendocrine tumours of the lung


www.intechopen.com


Kaufmann O, Georgi T, Dietel M. Utility of 123I3 monoclonal antibody against CD56 (NCAM) for the diagnosis of small cell carcinomas on paraffin sections. Hum Pathol 1997;28:1373-1378


Muller NL, Miller RR. Neuroendocrine carcinomas of the lung. Semin Roentgenal 1990;25:96-104


Neuroendocrine Tumours of the Lung


Travis WD, Brambilla E, Muller-Hermelink H, harris C. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Lung, Plaura, Thymus and Heart. Lyon, France. IARC Press; 2004


Van Lommel A. Pulmonary neuroendocrine cells (PNEC) and neuroepithelial bodies (NEB): chemoreceptors and regulators of lung development. Paediatric Respir Rev 2001;2:171-176


7.7 The neuroendocrine differentiation in lung tumours


Yesner R. Heterogeneity of so-called neuroendocrine lung tumors. Exp Mol Pathol 2001; 70:179-182

7.8 Embryological signalling pathways in lung tumours


Neuroendocrine Tumours of the Lung


Miki M, Ball DW, Linnoila I. Insights into the achaete-scute homoog-1 gene (hASH1) in normal and neoplastic human lung. Lung Cancer 2011;


Nasgashio R, Sato Y, Matsumoto T, Kageyama T, et al. The balance between the expression of hASH1 and HES1 differs between large cell neuroendocrine carcinoma and small cell carcinoma of the lung. Lung Cancer 2011;


Nie L, Xu M, Vladimirova A, Sun XH. Notch induce E2A ubiquitination and degradation are controlled by MAP kinase activities. EMBO J 2003;22:5780-5782.


www.intechopen.com


7.10 The neuroendocrine pathway of differentiation


Wissman C, Wild PJ, Kaiser S, et al. WIF1, a component of the Wnt pathway, is downregulated in prostate, breast, lung and bladder cancer. J Pathol 2003; 201:204-212


Zayzafoon M, Abdulkadir SA, McDonald JM. Noth signaling and ERK activation are important for the osteomimetic properties of prostate cancer bone metastatic cell lines. J Biol Chem 2004; 279:3662-3670

www.intechopen.com
The developments in molecular medicine are transforming respiratory medicine. Leading clinicians and scientists in the world have brought their knowledge and experience in their contributions to this book. Clinicians and researchers will learn about the most recent advances in a variety of lung diseases that will better enable them to understand respiratory disorders. This treatise presents state of the art essays on airways disease, neoplastic diseases, and pediatric respiratory conditions. Additionally, aspects of immune regulation, respiratory infections, acute lung injury/ARDS, pulmonary edema, functional evaluation in respiratory disorders, and a variety of other conditions are also discussed. The book will be invaluable to clinicians who keep up with the current concepts, improve their diagnostic skills, and understand potential new therapeutic applications in lung diseases, while scientists can contemplate a plethora of new research avenues for exploration.

**How to reference**

In order to correctly reference this scholarly work, feel free to copy and paste the following:
